# Bambusa Therapeutics

> Bambusa Therapeutics is a Boston clinical-stage biotechnology company developing long-acting bispecific antibodies for chronic immunological and inflammatory diseases. BBT001 combines IL-4Rα and IL-31 targeting for inflammatory skin disease; BBT002 combines IL-4Rα and IL-5 targeting for Type 2 respiratory disease. Its model pairs complementary targets with antibody engineering, half-life extension and subcutaneous delivery.

- **Founded:** 2024
- **Headquarters:** Boston, United States
- **Founders:** Shanshan Xu (Founder and Chief Executive Officer), Helmut Jeggle (Co-Founder and board member), Thang Ho (Co-Founder and Chief Development Officer (October 2026 release))
- **Products:** BBT001, BBT002, BBT003, BBT004
- **Notable:** Two programs entered clinical testing within approximately 12 months of the May 2024 founding., U.S. FDA cleared the BBT001 IND in May 2025., Reported preliminary randomized BBT001 patient data in July 2026.

## Products & services

- **BBT001** — Investigational half-life-extended bispecific antibody targeting IL-4Rα and IL-31. Early clinical development in atopic dermatitis and chronic spontaneous urticaria; subcutaneous atopic dermatitis cohort began dosing in October 2026.
- **BBT002** — Investigational half-life-extended bispecific antibody targeting IL-4Rα and IL-5. Phase 1b/2a development in COPD and chronic rhinosinusitis with nasal polyps; broader indications remain development ambitions.
- **BBT003** — Preclinical program for inflammatory bowel disease and other gastroenterological conditions; mechanism not disclosed.
- **BBT004** — Preclinical program for rheumatological and autoantibody-driven autoimmune diseases; mechanism not disclosed.

## Achievements

- Two programs entered clinical testing within approximately 12 months of the May 2024 founding.
- U.S. FDA cleared the BBT001 IND in May 2025.
- Reported preliminary randomized BBT001 patient data in July 2026.
- Reported preliminary BBT002 healthy-volunteer data at ATS 2026.
- Initiated BBT001 subcutaneous dosing on October 1, 2026.

## Latest updates

- **2026-10** — First patient dosed in the BBT001 subcutaneous cohort in New Zealand; up to 45 patients planned across multiple regions.
- **2026-07** — Preliminary BBT001 atopic dermatitis results reported from 17 patients at the June 8 data cutoff.
- **2026-07** — Howard Liang appointed to board and scientific advisory board established.
- **2026-06** — Presented preliminary multiple-ascending-dose BBT002 data at EAACI 2026.
- **2026-05** — Presented preliminary BBT002 single-dose data at ATS and announced first nasal-polyps trial patient dosed.

## Links

- Website: https://bambusatx.com/
- LinkedIn: https://www.linkedin.com/company/bambusatherapeutics/

---

Profile page: https://yespress.io/bambusa-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-10-05